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Abstract 
 
Introduction 
Genetic background has known to be associated with the outcome of human T cell lymphotropic virus 
(HTLV) type I infection. In The present study we investigate the association between GM-CSF gene 
polymorphisms with the outcome of HTLV-I infection. 
Materials and Methods 
We analyzed 3 single-nucleotide polymorphisms in the promter region of granulocyte macrophage colony 
stimulating factor (GM-CSF) at positions -677*A/C, -1440*A/G and -1916*T/C in 68 patients with HTLV-
I–associated myelopathy/tropical spastic paraparesis (HAM/TSP) and 77 HTLV-I-seropositive asymptomatic 
carriers and 175 healthy controls from an area in Iran, Mashhad, where HTLV-I is endemic.  
Results 
No significant differences were observed in the distribution of GM-CSF polymorphisms between HAM/TSP 
patients, HTLV-I carriers and healthy controls (P> 0.05). The -677*A/C polymorphism fall within the 
transcriptional enhancer factor-2 (TEF-2) binding site, so an electrophoretic mobility shift assay (EMSA) 
was performed to determine the effects of polymorphisms on protein binding to the GM-CSF promoter. The 
result showed a significantly higher binding efficiency of nuclear protein to the A allele compared with the C 
allele. 
Conclusion 
Our study suggests that polymorphisms in the GM-CSF promoter is not associated with the outcome of 
HTLV-I infection, however, GM-CSF polymorphism at position -677 could indeed influence gene 
expression. 
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Introduction 
Human T cell lymphotropic virus type I 
(HTLV-I) is an exogenous retroviruses which 
is associated with adult T cell leukaemia 
(ATL) and a progressive neurologic disorder 
named HAM/TSP (1, 2). This virus is endemic 
in South-West Japan, parts of Africa and South 
America (3-6). The North-East part of Iran 
(Mashhad) has been recognized as an endemic 
area for HTLV-I infection. The prevalence of 
HTLV-I infection in the whole population of 
Mashhad and blood donors is 3% and 0.44%, 
respectively (7, 8).  
It is poorly understood why the majority 
(95%) of HTLV-I-infected individuals remain 
asymptomatic carriers of the virus and less 
than 5% develop HTLV-I-associated diseases.  
Viral variation and host genetic factors, both 
may contribute to diseases susceptibility in 
HTLV-I infected-individuals (9, 10). It has 
been shown that there is no association 
between HTLV-I variants and susceptibility to 
HAM/TSP (11). However, Furukawa et al, 
demonstrated that a variant of the Tax gene is 
more frequently observed in patients with 
HAM/TSP compared with HTLV-I 
asymptomatic carriers (9), which may suggest 
infection with HTLV-I alone is not sufficient 
to cause HAM/TSP. 
  More recently Birmann et al, showed that 
the dysregulation of host immune response 
contributes to differences in natural history of 
HTLV-I infection in Japanese and Jamaican 
population. (12). Therefore, host genetic 
background may have a pivotal role in the 
efficiency of immune response to HTLV-I and 
pathogenesis of HTLV-I progression. A 
number of possible candidate genes such as 
human leukocyte antigen (HLA) class I and II, 
and cytokine gene polymorphisms have been 
implicated in HTLV-I infection (10, 13-18). 
Studies have shown that both cytokine gene 
polymorphisms and HTLV-I tax protein up-
regulate cytokine production level. The 
promoter region of many genes including 
interleukin 2 (IL-2), transforming growth 
factor  β (TGB-β), IL-15, IL-6 and GM-CSF 
contain nuclear factor kappa binding (NF-κB) 
sites and transactivitated by HTLV-I tax 
protein (19).  
GM-CSF is a growth factor known to be a 
potential factor in stimulating, proliferation, 
maturation and function of hematopoietic cells 
(20). GM-CSF has a not only variety effects 
on regulation, differentiation and proliferation 
of hematopoietic progenitors cells, but also it 
regulates the function of mature cells such as 
monocytes, macrophages, DCs cells and NK 
cells.  
The 5’-flanking region of human GM-CSF 
contain many transcription factors binding 
sites (21).We have previously detected novel 
polymorphisms in the human GM-CSF gene at 
positions –677*A/C and -1916. There was no 
significant association between GM-CSF gene 
polymorphisms at position -677*A/C and –
1916*T/C and GM-CSF production on 
stimulated peripheral blood mononuclear 
(PBMC) by enzyme linked immunosorbent 
assay (ELISA). We found association between 
-677 gene polymorphism and the frequency 
and severity of atopic dermatitis (22).  The -
677 polymorphism seem to fall within the 
transcriptional enhancer factor-2 (TEF-2) 
binding site. TEF-2 binds to the enhancer of 
simian virus 40 (SV40) and to the CACCC 
box of the human β-globin promoter (23, 24).   
The role of GM-CSF in HTLV-I infection 
has not been studied very well. In other 
retroviral infection such as HIV, it is 
demonstrated that GM-CSF stimulates 
monocytes and monocytes derived 
macrophages to produce chemokines including 
RANTES, MIP-1α and MIP-1β which leads 
these chemokines bind to chemokine receptor 
5 (CCR5) and modulate human 
immunodeficiency virus (HIV) infection in T 
cells and macrophages (25, 26).  Furthermore, 
GM-CSF augments the immune response to 
vaccines directly against both infectious agents 
and various cancers (27, 28). Coimmunization 
with GM-CSF enhances both the antibody and 
T cell proliferation response (29, 30). 
Therefore, it seems that GM-CSF might have a 
role in immune response against HTLV-I 
infection and single nucleotide polymorphisms 
in GM-CSF gene is associated with GM-CSF 
production and HTLV–I infection. 
In the present study we aimed to assess the 
effect of GM-CSF -677*A/C gene 
polymorphism on TEF-2 binding site and also  
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investigate the association of GM-CSF gene 
polymorphisms at positions -677*A/C, -
1440*A/G and -1916*T/C with the outcome of 
HTLV-I infection in the North-east of Iran. 
 
Materials and Methods 
Samples collection 
All participant enrolled in the study attended 
Ghaem Hospital, Mashhad University of 
Medical Sciences, Iran. The populations 
studied were 155 healthy controls, 77 
randomly selected HTLV-I asymptomatic 
carriers and 68 HAM/TSP patients who 
fulfilled the accepted criteria for HAM/TSP 
(18). The mean age of HAM/TSP patients was 
45±9.8 years (range 24-74), and the female to 
male ratio was 1.5. The clinical and laboratory 
findings of HAM/TSP patients have been 
described previously (18). Blood samples from 
HTLV-I carriers and healthy controls were 
obtained from subjects attending the Mashhad 
blood transfusion centre. The mean age of the 
asymptomatic carriers was 37.6±10.2 years, 
and 23 of the 77 carriers were women (36.5%). 
The mean age of the healthy controls was 
34.4±8.1years. Permission to conduct the 
study was obtained from the Ethics 
Committees of Mashhad University of 
Medical Sciences and the Mashhad blood 
transfusion centre and informed consent was 
obtained from all cases and healthy controls. 
 
GM-CSF genotyping 
DNA  was  extracted  from  6  ml  EDTA           
whole blood samples using a standard 
phenolchloroform method. Amplification 
refractory mutation system (ARMS)- polymerase 
chain reaction (PCR) was used for genotyping 
of single nucleotide substitution at positions -
677*A/C and -1916*T/C of GM-CSF (22). 
PCR- Single-Stranded Conformational 
Polymorphism (SSCP) method was used for 
genotyping of -1440*A/G polymorphism. The 
details of method have been described 
previously (18).  
 
Electrophoretic mobility gel shift assay 
(EMSA) 
Ologonucleotide probes (27 mer) were designed 
to cover the region surrounding the A to C –677 
GM-CSF polymorphism. Consensus and mutant 
TEF-2 competitor single-stranded 
oligonucleotides (20 mer) were also designed. 
The sequences of oligonucleotide probes are 
shown in Table 1, polymorphic sites are in bold 
and the site of the mutant region is underlined.  
Oligonucleotides were annealed to form 
double stranded probes. In this case, each 
single stranded nucleotide was made up at               
1 µg/µl concentration with dH2O, then 10 µl of 
each sense and antisense complementary 
strand of DNA were combined with 0.5 µl 5 M 
NaCl, 4.5 µl 10 mM tris HCl (pH 8.5). The 
contents were incubated in a PCR machine as 
follow: 95 °C for 5 min, 65 °C for 10 min and 
37 °C for 10 min and then cooling down for    
1 hr at room temperature. Then 3.5 µl of 5 M 
NaCl and 75 µl of 10 mM Tris-HCl (pH 8.5) 
were added to make up a final concentration of 
0.1  µg/µl oligonucleotide probe. Then 5 µl                   
(5  ρmoles) of oligonucleotide probe was 
transferred to an Eppendorf tube and 5 µl of 
Kinase reaction buffer, 1 µl of T4-
polynucleotide  kinase  (Gibco  BRL,  UK),     
2.5  µl  [γ
-32  P]-ATP
  and 11.5 µl dH2O were 
added to end-label double stranded DNA. The 
contents were briefly centrifuged to collect the 
solution and incubated at room temperature for 
1 hr. The reaction was stopped by adding of   
75 µl of Tris-EDTA (TE) buffer (5 mM). Then 
the labelled probes were separated from 
unlabelled probe by using a prepacked spin 
column containing Sephadex G-50 (Amersham 
Pharmacia Biotech, UK). The materials and 
method of EMSA reaction and electrophoresis 
have been described previously (31). 
 
Statistical analysis 
Differences in GM-CSF alleles and genotype 
between patients with HAM/TSP, HTLV-I 
asymptomatic carriers and healthy controls 
were performed, using STATA version 11 
(STATA Corp.,). The significance of 
differences in allele and genotype frequencies 
among all groups were established, using the 
Fisher exact test and by calculation of odds 
ratios (OR) with 95% confidence intervals 
(95% CI). The significance of genotype 
frequency differences between any of the three 
groups were examined by the Chi-squared test. 
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Results 
Association between GM-CSG gene 
polymorphisms and HTLV-I infection 
The allele and genotype frequencies of the 
three GM-CSF polymorphisms at position-
677*A/C, -1440*A/G and -1916*T/C were 
determined to compare any differences 
between HAM/TSP patients, HTLV-I carriers 
and healthy controls. 
The GM-CSF -677*A allele was more 
frequent in HAM/TSP patients (82.3%) and 
HTLV-I carriers (82.5%) compared with 
healthy controls (76.8%), but no statistical 
significant difference was observed between 
HAM/TSP  patients  and  healthy  controls       
(P= 0.18), HTLV-I carriers and healthy 
controls (P= 0.15), or HAM/TSP patients and 
HTLV-I carriers (P= 0.97) (Table 1).  
The distribution of alleles and genotypes of 
the GM-CSF -1440*A/G polymorphism was 
the same in HAM/TSP patients, healthy 
controls and HTLV-I carriers (Table 3-16). No 
significant differences in allele and genotype 
frequencies in the GM-CSF -1440*A/G 
polymorphism were identified between any of 
the three groups (P> 0.05). 
Genotype and allele frequency analysis of 
healthy controls, HTLV-I carriers and 
HAM/TSP patients was performed for the T to C 
substitution at position –1916 of the GM-CSF 
gene (Table 1). The distribution of the allele T 
was the same between all of the three groups and 
no significant differences were observed 
between any of the three groups (P> 0.05). 
 
Effects of GM-CSF –677 gene polymorphism 
on transcription factor binding 
EMSA was used to assess the effect of           
GM-CSF -677*A/C gene polymorphism on 
transcription factor binding. For the binding 
assay, HeLa nuclear extract was used as a 
source of transcription factor. Two double-
stranded oligonucleotides probe (27 bp) each 
representing either the -677*AA or -677 *CC 
genotype were made and labelled with γ-
32 
ATP. Both probes cover the region of GM-
CSF from –689 to –663. HeLa nuclear protein 
extract was incubated with either the labeled-
677*A or the –677*C probe using consensus 
and mutant TEF-2 oligonucleotides 
competitor. Then, electrophoresis was 
performed using 4% acrylamide gel. 
Incubation of nuclear extract from HeLa cell  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. EMSA assay of specific binding of A probe of 
the GM-CSF –677 gene by nuclear protein extract from 
HeLa cell. Nuclear extract from Hela cells was 
incubated with radiolabelled GM-CSF -6778*A 
oligonucleotide. The protein/DNA complex can be seen 
in lane 2. The oligonulcleotide without HeLa cell 
extract was run in lane 1 (negative control) and there 
was no band apparent. Preincubation of the HeLa cell 
extract for 20 min with either unlabelled TEF-2 
consensus or -677*A allelic oligonucleotides inhibited 
the formation of the DNA/protein complex (lanes 3 and 
5, respectively) compared with lane 2. By contrast, a 
scrambled TEF-2 oligonucleotide or the -677*C 
sequence did not inhibit formation of the DNA/protein 
complex (lanes 4 and 6, respectively). Similar 
experiments with a radiolabelled -677*C 
oligonucleotide gave similar results (data not shown).  
 
with radio labelled GM-CSF -677*A probe 
gave  a  protein/DNA  complex  (lane  6)          
(Figure 1).  
No band was apparent when oligonucleotide 
was incubated without HeLa cell  extract        
(lane 1). When the nuclear protein extracts 
from HeLa cell was incubated with either 
unlabelled TEF-2 consensus or -677*A probe, 
an inhibition in the formation of the 
DNA/protein complex was observed (lanes  3 
and 5, respectively) compared with lane 6 
(HeLa cell extract and labelled -677*A probe). 
When mutant TEF-2 or -677*C unlabelled 
probes were added, the formation of the 
complex was reduced by labelled -677*A 
allelic oligonucleotide (lanes 4 and 6, 
respectively). The experiments with a radio 
labelled -677*C oligonucleotide were 
performed, and gave similar results.  
Taken together, this preliminary result may 
suggest that the presence of a functional TEF-
2 binding motif in the promoter region of the 
GM-CSF gene, and that transcription factor 
binding is greater to the A, compared with the 
C, allelic variant of the GM-CSF sequence. 
6 5 4 3 2 1 
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Table 1. Sequences of oligonucleotide probes of GM-CSF.   
Name   Sequencing of primers 
GM-CSF “C” sense                                       5’-CTT GAC CCAGCCCCACCCCCTCTGAAG-3’ 
GM-CSF “C” anti-sense                               5’-CTTCAGAGGGGGTGGGGCTGGGTCAAG-5’ 
GM-CSF “A” sense                                        5’- CTT GAC CCAGCCACACCCCCTCTGAAG-3’ 
GM-CSF “A” anti-sense                                5’- CTTCAGAGGGGGTGTGGCTGGGTCAAG-3’ 
TEF-2 (consensus) sense              5’-GATCCTTAGGGTGTGGACCA-3’ 
TEF-2 (consensus) anti-sense       5’-TGGTCCACACCCTAAGGATC-3’ 
TEF-2 (mutant) sense  5’-GATCCTTACCCACTGGACCA-3’ 
TEF-2 (mutant) anti-sense            5’-TGGTCCAGTGGGTAAGGATC-3’ 
Polymorphic sites are in bold and the site of the mutant region is underlined. 
Discussion 
It is well known that GM-CSF has ability to 
induce proliferation and differentiation of 
myeloid progenitor’s cells. The capacity of 
cytotoxicity and antigen presenting by 
granulocytes and macrophages are increased 
by GM-CSF (20). 
Production of many cytokines is under 
genetic control and GM-CSF may not be 
excluded from this phenomenon. In the present 
study we compared the allele and genotype 
frequencies of three GM-CSF polymorphisms 
at positions -677*A/C, -1440*A/G and -
1916*T/C among HAM/TSP patients, HTLV-I 
asymptomatic carriers and healthy controls. 
The analysis of genotype and allele 
frequencies of these polymorphisms showed 
there is no significant difference between 
HAM/TSP and HTLV-I carriers, HAM/TSP 
and healthy controls and HTLV-I carriers and 
healthy controls (Table 2). Although, the 
frequencies of -677*C, -1440*G and -1916*C 
alleles were slightly increased in HAM/TSP 
patients and HTLV-I carriers compared with 
healthy controls, however, the result did not 
reach significant levels. This may be due to the 
small numbers of HAM/TSP patients and 
HTLV-I carriers. Recently, we found that there 
is a association between GM-CSF gene 
polymorphisms  at  position  -677*A/C  and            
-1916*T/C in patients with severity of atopic 
dermatitis. Our results identified that the 
frequencies of -677*A and -1916*T allele are 
greater in children with atopic dermatitis than 
in control group (P< 0.05) (22). Inheritance of 
a GM-CSF -1916*T allele compared with a C 
allele was associated with doubling of the 
frequency of atopic dermatitis (P< 0.001). This 
result is consistent with the previous 
observations that suggest alteration in GM-
CSF levels in the skin is associated with 
variation in the severity of atopic dermatitis 
(32). Although, activated T cells and B cells 
are the major source of GM-CSF production, 
other cells such as astrocytes and microglial 
cells are able to produce GM-CSF (33). The 
production of GM-CSF is not detectable under 
normal conditions. Furthermore, the GM-CSF 
gene is under the regulation of transcription 
factors such as NF- κB and nuclear factor-
activated T cells (NF-AT) (34). Therefore, it 
seems that stimulation of relevant cells by 
suitable induction signals may lead to up 
regulation of GM-CSF and polymorphism in 
the promoter region may act in a cell specific-
manner.  
There has been considerable interest in the 
role of GM-CSF in other retroviral infections 
such  as  HIV.  Stimulation  of  peripheral        
blood monocytes and monocyte-derived 
macrophages by GM-CSF leads to induction 
of chemokines such as regulation of activation 
of normal T cell expressed and secreted 
(RANTES) F, Macrophage-inflammatory 
protein (MIP)-1α and MIP-1β. These 
inflammatory chemokines bind to HIV 
coreceptor, CCR5 and modulate HIV infection 
in T cells and macrophages (26). In vitro 
studies have shown that GM-CSF induced 
monocytes to differentiate to macrophages and 
also suppressed the mRNA expression of 
CXCR4 and CCR5 which leading to decreased 
HIV entry to these cells (25). In contrast to this 
effect, Wang et al reported that addition of 
GM-CSF to monocyte culture before and 
during infection with HIV increased both the 
extent of HIV entry and replication as well as 
CCR5 expression (35).   
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Table 2. Genotype and allele frequency in HAM/TSP patients, HTLV-I carriers and healthy controls. 
GM-CSF 
Polymorphisms 
Controls 
Total =157 
n (%) 
HAM/TSP 
Total =68 
n (%) 
Carriers 
Total =77 
n (%) 
P value 
HAM/TSP vs 
carriers 
P value 
HAM/TSP 
vs controls 
P value 
Carriers vs 
controls 
-677 
Genotype 
        
AA  93 (59.2)  48 (70.6)  53 (68.9)  0.77  0.22  NS* 
AC 
 
CC 
55 (35.0) 
 
9 (5.8) 
16 (23.5) 
 
4 (5.9) 
21 (27.2) 
 
3 (3.9) 
   
 
 
Allele           
A  241 (76.8)  112 (82.3)  127 (82.5)  0.97  0.18  NS 
C 
 
-1440 
Genotype 
73 (23.2)  24 (17.7)  27 (17.5) 
 
 
 
 
   
AA                    87 (55.4)  46 (67.6)  50 (64.9)  0.73  0.11  NS 
AG 
 
GG 
64 (40.8) 
 
6 (3.8) 
18 (26.5) 
 
4 (5.9) 
24 (31.2) 
 
3 (3.9) 
   
Allele          
A  238 (75.8)  110 (80.9)  124 (80.5)  0.93  0.23  NS 
G 
 
-1916 
76 (24.2)  26 (19.1)  30 (19.5)       
Genotype          
TT  86 (55.0)  46 (67.6)  49 (63.6)  0.82  0.16  NS 
CT 
 
CC 
62 (39.0) 
 
9 (6.0) 
18 (26.5) 
 
4 (5.9) 
25 (32.5) 
 
3 (3.9) 
   
Allele          
T  234 (75.0)  110 (80.9)  123 (79.9)  0.82  0.14  NS 
C  80 (25.0)  26 (19.1)  31 (20.1)       
No significant (NS)* differences were observed in allele and genotype frequencies between any of the three groups. 
 
 
We proposed that the -677*C, -1916*C and  
-1440*G alleles are more common in patients 
infected with HTLV-I compared with controls; 
however, our results did not reach a significant 
level. It is likely that these polymorphisms 
may be a useful genetic marker for HIV, 
because no known role has been recognized 
for the entry of HTLV-I through CCR5.    
Short oligonucleotides representing either 
the GM-CSF -677*A or the GM-CSF -677*C 
genotype of the GM-CSF promoter were 
designed to investigate whether the GM-CSF          
-677*A/C polymorphism affects transcription 
factor binding. The results identified the 
presence of a functional TEF-2 binding site in 
the promoter region of GM-CSF, with greater 
affinity of the allelic variant A than the C 
allele. The greater affinity of TEF-2 to GM-
CSF -677*A may suggest that A to C 
substitution at position-677 weakens the 
binding of TEF-2 to the promoter of GM-CSF 
and may strengthen the promoter activity of 
GM-CSF when allele A is present at the 
polymorphic site. This experiment should be 
confirmed by super gel shift and reporter gene 
assays to investigate if -677*A/C 
polymorphism affects transcription of GM-
CSF.  
 
Conclusion 
Our results showed that there is no association 
between GM-CSF gene polymorphisms and 
the outcome of HTLV-I-individuals in the 
North east of Iran. Other studies in different 
population infected with HTLV-I may be 
useful to clarify the role of GM-CSF gene 
polymorphism in HTLV-I infection. 
Furthermore, the effect of another transcription  
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factor,  TCF,  which  is  located  close  to  the        
–677*A/C polymorphism may be, involved in 
the induction of GM-CSF transcription. 
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